{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:56:56Z","timestamp":1787061416080,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.ijantimicag.2004.02.017","type":"journal-article","created":{"date-parts":[[2004,5,29]],"date-time":"2004-05-29T02:54:22Z","timestamp":1085799262000},"page":"533-546","source":"Crossref","is-referenced-by-count":22,"title":["Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin"],"prefix":"10.1016","volume":"23","author":[{"given":"P.C","family":"Appelbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J","family":"Burley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB1","unstructured":"Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: Final Data for 2000. National vital statistics reports, vol. 50. Hyattsville, Maryland: National Center for Health Statistics; 2002."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB2","first-page":"1184","article-title":"Chronic obstructive pulmonary disease surveillance\u2014United States, 1971\u20132000","volume":"47","author":"Mannino","year":"2002","journal-title":"Respir. Care"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB3","unstructured":"Hall MJ, Owings MF, 2000. National Hospital Discharge Survey. Advance data from vital and health statistics. Hyattsville, Maryland: National Center for Health Statistics; 2002."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00000441-196509000-00003","article-title":"Susceptibility of pneumococci to nine antibiotics","volume":"250","author":"Kislak","year":"1965","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM197101282840403","article-title":"Increased resistance to penicillin of pneumococci isolated from man","volume":"284","author":"Hansman","year":"1971","journal-title":"N. Engl. J. Med."},{"issue":"Topic T1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jac.a020891","article-title":"The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project","volume":"46","author":"Schito","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM197810052991402","article-title":"Emergence of multiply resistant pneumococci","volume":"299","author":"Jacobs","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB10","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200012283432603","article-title":"Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States","volume":"343","author":"Whitney","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archinte.157.15.1709","article-title":"Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio","volume":"157","author":"Marston","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1164\/ajrccm.152.4.7551387","article-title":"Community-acquired pneumonia: impact of immune status","volume":"152","author":"Mundy","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005792-199009000-00004","article-title":"New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases","volume":"69","author":"Fang","year":"1990","journal-title":"Medicine"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thorax.56.4.296","article-title":"Study of community-acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines","volume":"56","author":"Lim","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinids\/11.4.586","article-title":"Community-acquired pneumonia requiring hospitalization: 5-year prospective study","volume":"11","author":"Marrie","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1469-0691.2003.00602.x","article-title":"Microbiological etiology in clinically diagnosed community-acquired pneumonia in primary care in \u00d6rebro","volume":"9","author":"Lagerstr\u00f6m","year":"2003","journal-title":"Sweden Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB17","unstructured":"Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: WB Saunders; 1992. p. 476\u201385."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jac\/30.1.89","article-title":"Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomised, double-blind trial","volume":"30","author":"Lindsay","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jac\/43.4.529","article-title":"Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study","volume":"43","author":"Shah","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/47.1.67","article-title":"and the Amoxycillin Bronchitis Study Group. Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1g bd with amoxycillin 500mg tds in the treatment of acute exacerbation of chronic bronchitis","volume":"47","author":"Georgopoulos","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0924-8579(01)00435-6","article-title":"The Study Group. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis","volume":"18","author":"Masterton","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB22","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia","volume":"163","author":"Niederman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB23","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archinte.1997.00440360129015","article-title":"Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Group","volume":"157","author":"Marston","year":"1997","journal-title":"Arch. Intern. Med."},{"issue":"Suppl. IV","key":"10.1016\/j.ijantimicag.2004.02.017_BIB24","first-page":"iv1","article-title":"BTS guidelines for the management of community-acquired pneumonia in adults","volume":"56","author":"Macfarlane","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB25","unstructured":"American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema. A statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis 85;1962:762\u201368."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ije\/6.2.107","article-title":"Quantitative relationships between cigarette smoking and chronic productive cough","volume":"6","author":"Burrows","year":"1977","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1164\/ajrccm\/146.2.413","article-title":"Exposure-response relationships between occupational exposures and chronic illness: a community-based study","volume":"146","author":"Xu","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1183\/09031936.94.07061032","article-title":"Occupation and chronic obstructive pulmonary disease (COPD)","volume":"7","author":"Burge","year":"1994","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1164\/ajrccm\/146.1.177","article-title":"Latent adenoviral infection in the pathogenesis of chronic airways obstruction","volume":"146","author":"Matsuse","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/rmed.2002.1454","article-title":"Haemophilus parainfluenzae infection of respiratory mucosa","volume":"97","author":"Middleton","year":"2003","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/CDLI.7.1.25-30.2000","article-title":"Immune response to Haemophilus parainfluenzae in patients with chronic obstructive lung disease","volume":"7","author":"Mitchell","year":"2000","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1378\/chest.113.6.1542","article-title":"Infective exacerbations of chronic bronchitis. Relationship between bacteriologic etiology and lung function","volume":"122","author":"Eller","year":"1998","journal-title":"Chest."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1378\/chest.116.1.40","article-title":"Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD","volume":"116","author":"Miravitlles","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB35","doi-asserted-by":"crossref","first-page":"380S","DOI":"10.1378\/chest.117.5_suppl_2.380S","article-title":"Infectious etiology of acute exacerbations of chronic bronchitis","volume":"117","author":"Sethi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/ajrccm.160.1.9809041","article-title":"Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection","volume":"160","author":"Mogulkoc","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0732-8893(01)00255-3","article-title":"Infectious etiologies in acute exacerbation of COPD","volume":"40","author":"Lieberman","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000195745","article-title":"Host-microbe relationships in chronic respiratory infection","volume":"55","author":"Cole","year":"1989","journal-title":"Respiration"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1164\/ajrccm\/146.4.1067","article-title":"Bacterial infection in chronic obstructive pulmonary disease","volume":"146","author":"Murphy","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB40","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1164\/ajrccm.161.5.9908022","article-title":"Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease","volume":"161","author":"Seemungal","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0149-2918(02)85139-6","article-title":"A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes","volume":"24","author":"Wilson","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMoa012561","article-title":"New strains of bacteria and exacerbations of chronic obstructive pulmonary disease","volume":"347","author":"Sethi","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMe020075","article-title":"Bacteria and exacerbations of chronic obstructive pulmonary disease","volume":"347","author":"Anthonisen","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"Topic T1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone generations: natural history or natural selection","volume":"46","author":"Ball","year":"2000","journal-title":"J. Antimicrob. Chemother"},{"issue":"Suppl. S1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/45.suppl_3.1","article-title":"Comparative in vitro activity of gemifloxacin","volume":"45","author":"King","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0924-8579(03)00060-8","article-title":"Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae","volume":"21","author":"Waites","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.9.2.383","article-title":"A review of clinical trials with fluoroquinolones with an emphasis on new agents","volume":"9","author":"Blondeau","year":"2000","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1034\/j.1399-3003.1999.14a38.x","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract","volume":"14","author":"Wise","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB50","first-page":"415","article-title":"Iannini PB. A profile of gemifloxacin, a new respiratory fluoroquinolone","volume":"21","author":"File","year":"2003","journal-title":"Today\u2019s Therapeutic Trends"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1198-743x.2001.00295.x","article-title":"Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters","volume":"7","author":"Jacobs","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/45.suppl_3.101","article-title":"Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones","volume":"45","author":"Morrissey","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB53","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1128\/AAC.44.11.3112-3117.2000","article-title":"Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro","volume":"44","author":"Heaton","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/107662903764736300","article-title":"Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation","volume":"9","author":"Gillespie","year":"2003","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0966-842X(97)01101-3","article-title":"The biological cost of antimicrobial resistance","volume":"5","author":"Gillespie","year":"1997","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/335351a0","article-title":"Evolution of a bacteria\/plasmid association","volume":"335","author":"Bouma","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB57","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/AAC.43.8.1866","article-title":"Physiological cost of rifampicin resistance induced in vitro in Mycobacterium tuberculosis","volume":"43","author":"Billington","year":"1999","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0924-8579(99)00043-6","article-title":"Selection of resistant variants of respiratory pathogens by quinolones","volume":"12","author":"Sefton","year":"1999","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/107662902760190617","article-title":"Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae","volume":"8","author":"Gillespie","year":"2002","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/jac\/dkg329","article-title":"Analysis of dual active fluoroquinolones in Streptococcus pneumoniae","volume":"52","author":"Fisher","year":"2003","journal-title":"J. Antimicrob. Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB61","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1128\/AAC.44.11.3112-3117.2000","article-title":"Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro","volume":"44","author":"Heaton","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.76.6.505","article-title":"The specific polysaccharide content of pneumonic lungs","volume":"76","author":"Frisch","year":"1942","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.46.2.267-274.2002","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective","volume":"46","author":"Gillespie","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB64","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/AAC.44.2.304-310.2000","article-title":"Antipneumococcal activities of gemifloxacin compared to those of nine other agents","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB65","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.44.3.633-639.2000","article-title":"Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/45.suppl_3.13","article-title":"In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA","volume":"45","author":"McCloskey","year":"2000","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB67","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF01966996","article-title":"The mode of action of quinolones: the paradox inactivity of low and high concentrations and activity in the anaerobic environment","volume":"10","author":"Lewin","year":"1991","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1099\/00222615-43-1-4","article-title":"Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a","volume":"43","author":"Morrissey","year":"1995","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB69","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/jac\/38.6.1061","article-title":"Bactericidal activity of trovafloxacin (CP-99,219)","volume":"38","author":"Morrissey","year":"1996","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1099\/0022-1317-49-9-841","article-title":"The bactericidal activity of gemifloxacin (SB-265805)","volume":"49","author":"Morrissey","year":"2000","journal-title":"J. Med. Microbiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/45.suppl_3.107","article-title":"Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae","volume":"45","author":"Morrissey","year":"2000","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB72","unstructured":"Gemifloxacin (Factive\u00ae) Prescribing Information July 2003, Genesoft Pharmaceuticals, South San Francisco, CA."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/40.4.573","article-title":"Concentrations of levofloxacin (HR355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy","volume":"40","author":"Andrews","year":"1997","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB74","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/44.6.835","article-title":"Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy","volume":"44","author":"Soman","year":"1999","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB75","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.47.6.1867-1874.2003","article-title":"Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002","volume":"47","author":"Zhanel","year":"2003","journal-title":"Antimicrob. Agents Chemother"},{"issue":"Topic T1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jac.a020891","article-title":"The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project","volume":"46","author":"Schito","year":"2000","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB77","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/AAC.43.2.357","article-title":"and the Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996\u20131997) multicenter surveillance study","volume":"43","author":"Baquero","year":"1999","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB78","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999\u20132000, including a comparison of resistance rates since 1994\u20131995","volume":"45","author":"Doern","year":"2001","journal-title":"Antimicrob. Agents Chemother"},{"issue":"Suppl. S1","key":"10.1016\/j.ijantimicag.2004.02.017_BIB79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkf808","article-title":"Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin","volume":"50","author":"Felmingham","year":"2002","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0924-8579(02)00124-3","article-title":"Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US","volume":"20","author":"Karlowsky","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg321","article-title":"and the Alexander Project Group. The Alexander Project 1998\u20132000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents","volume":"52","author":"Jacobs","year":"2003","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB82","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/48.5.659","article-title":"Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000","volume":"48","author":"Ho","year":"2001","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB84","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1128\/AAC.46.8.2671-2675.2002","article-title":"Incidence, epidemiology and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia","volume":"46","author":"Pankuch","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB85","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJM199911113412013","article-title":"Fluoroquinolone resistance in Streptococcus pneumoniae","volume":"341","author":"Linares","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB86","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMoa012122","article-title":"Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia","volume":"346","author":"Davidson","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB87","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1128\/AAC.44.11.3008-3011.2000","article-title":"A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America and South America","volume":"44","author":"Hoban","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB88","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1128\/AAC.46.8.2665-2667.2002","article-title":"Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain","volume":"46","author":"P\u00e9rez-Trallero","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB89","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3201\/eid0907.020589","article-title":"Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance","volume":"9","author":"Lim","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB90","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0149-2918(02)80088-1","article-title":"Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone\/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability","volume":"24","author":"Lode","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/48.1.67","article-title":"049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin","volume":"48","author":"File","year":"2001","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0924-8579(01)00359-4","article-title":"Efficacy and safety of gemifloxacin 320mg once-daily for 7 days in the treatment of adult lower respiratory tract infections","volume":"18","author":"Ball","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB93","unstructured":"Leophonte P, File T, Feldman CA. Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid tid for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med, submitted for publication."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB94","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1179\/joc.2003.15.5.461","article-title":"Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases","volume":"15","author":"Santos","year":"2003","journal-title":"J. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB95","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1053\/rmed.2003.1435","article-title":"Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone\/oral cefuroxime (maximum 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis","volume":"97","author":"Wilson","year":"2003","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB96","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0149-2918(02)85139-6","article-title":"068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbation of chronic bronchitis and long-term clinical outcomes","volume":"24","author":"Wilson","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB97","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/AAC.46.6.1746-1754.2002","article-title":"Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment","volume":"46","author":"Finch","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB98","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB99","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompromised adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1179\/joc.2001.13.3.288","article-title":"069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin","volume":"13","author":"Ball","year":"2001","journal-title":"J. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB101","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1179\/joc.2000.12.4.314","article-title":"Gemifloxacin versus amoxicillin\/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group","volume":"12","author":"File","year":"2000","journal-title":"J. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB102","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/ajhp\/59.14.1357","article-title":"Cost-effectiveness of gemifloxacin: results from the GLOBE study","volume":"59","author":"Halpern","year":"2002","journal-title":"Am. J. Health Syst. Pharm"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB103","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.47.3.1017-1022.2003","article-title":"Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates","volume":"47","author":"Peric","year":"2003","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB104","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.317.7159.643","article-title":"The development of new antimicrobial agents","volume":"317","author":"Wise","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1473-3099(03)00539-5","article-title":"Antimicrobial resistance: can we see the wood for the trees","volume":"3","author":"Burley","year":"2003","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB106","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1378\/chest.117.5.1345","article-title":"Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD","volume":"117","author":"Adams","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB107","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1378\/chest.121.5.1449","article-title":"For the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD","volume":"121","author":"Miravitlles","year":"2002","journal-title":"Chest"},{"issue":"Suppl. A","key":"10.1016\/j.ijantimicag.2004.02.017_BIB108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/43.suppl_1.107","article-title":"Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis","volume":"43","author":"Destache","year":"1999","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.ijantimicag.2004.02.017_BIB109","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/thorax.58.7.589","article-title":"For the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis","volume":"58","author":"Spencer","year":"2003","journal-title":"Thorax"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T15:22:07Z","timestamp":1682695327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857904000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0924857904000913"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.02.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}